Protocol Ledger

NCT04919226 · Phase III · ACTIVE NOT RECRUITING

Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE

Interventional Phase III clinical trial protocol NCT04919226 sponsored by ITM Solucin in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-12-21 Enrollment: 259 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04919226
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)259 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04919226
Protocol FieldVerified Registry Value
NCT IdentifierNCT04919226
Consolidated Lead SponsorITM Solucin
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment259 participants (ACTUAL)
Registered Start Date2021-12-21
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI